Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898582 | 1.00 | CCNE1 (0.41) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL4889988 | 0.89 | PI4KA (0.42) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL4889999 | 0.89 | PI4KA (0.42) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL4893586 | 0.83 | APP (0.44) | CCNT1LMNAACHE | |
| SCHEMBL7152982 | 0.81 | MAPKAPK2 (0.38) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL7152990 | 0.81 | MAPKAPK2 (0.38) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| SCHEMBL7153615 | 0.81 | PIM1 (0.38) | EGFRCDK1PIM1 | |
| SCHEMBL7153609 | 0.81 | PIM1 (0.38) | EGFRCDK1PIM1 | |
| Hydrochloric Acid SCHEMBL4901100 | 0.81 | MAPKAPK2 (0.38) | CCNE1CDK2CCNE2CCNA2CCNA1 | |
| Hydrochloric Acid SCHEMBL4901111 | 0.81 | MAPKAPK2 (0.38) | CCNE1CDK2CCNE2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| EP-1347975-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2003-10-01 | — | — | EP | claimed |
| WO-2002051843-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2002-07-04 | — | — | WO | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | CCNE1 108/4885CDK2 10/4885CCNE2 508/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | CCNE1 86/4885CDK2 9/4885CCNE2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.